Overview

A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer

Status:
RECRUITING

Trial end date:
2027-03-22

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of cardunolizumab in combination with/without chemotherapy ± bevacizumab for recurrent or metastatic vulvar and vaginal cancers that are not amenable to radical treatment.

Phase:

PHASE2

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Collaborators:

Akeso
Innovent Biologics, Inc.